Jeff White

Another negative study trying to add anti-PD1/L1 to RT or chemoRT in locally advanced head and neck cancer

Ezra Cohen, Chief Medical Officer of Oncology Tempus Labs, Inc., shared on LinkedIn:

“This is another negative study trying to add anti-PD1/L1 to RT or chemoRT in locally advanced head and neck cancer. Nonetheless, there are some important takeaways about the population enrolled. We can define eligibility and there is a clinical need to find therapies for platin-ineligible patients. Furthermore, we now have prospective PFS and OS data to work from. Perhaps neoadjuvant IO in a biomarker selected cohort should be the next trial.”

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial – The Lancet Oncology

Authors: Prof Loren K Mell, Pedro A Torres-Saavedra, Prof Stuart J Wong, Prof Julie A Kish, Steven S Chang, Prof Richard C Jordan, Tian Liu, Prof Minh Tam Truong,  Prof Eric W Winquist, Vinita Takiar, Trisha Wise-Draper, Prof Jared R Robbins, Prof Cristina P Rodriguez, Musaddiq J Awan, Beth M Beadle, Christina Henson,  Samir Narayan, Prof Sharon A Spencer, Steven Powell, Prof Neal Dunlap, Assuntina G Sacco, Prof Kenneth Shung Hu, Henry S Park, Prof Julie E Bauman, Jonathan Harris, Prof Sue S Yom, Quynh-Thu Le.

Assuntina G Sacco Beth M Beadle cancer Christina Henson Ezra Cohen Henry S. Park Jonathan Harris Musaddiq J Awan OncoDaily Oncology Pedro A Torres-Saavedra Prof Cristina P Rodriguez Prof Eric W Winquist Prof Jared R Robbins Prof Julie A Kish Prof Julie E Bauman Prof Kenneth Shung Hu Prof Loren K Mell Prof Minh Tam Truong Prof Neal Dunlap Prof Richard C Jordan Prof Sharon A Spencer Prof Stuart J Wong Prof Sue S Yom Quynh Thu Le Samir Narayan Steven Powell Steven S Chang Tian Liu Trisha Wise-Draper Vinita Takiar